| Entries |
| Document | Title | Date |
|---|
| 20090247582 | METHODS OF TREATING ATHEROSCLEROSIS - The present invention relates to a method for the prevention, delay the onset and treatment of atherosclerosis which method comprises administering to a warm-blooded animal, in need thereof, a therapeutically effective amount of a renin inhibitor, or a pharmaceutically acceptable salt thereof, alone or in combination with at least one therapeutic agent selected from the group consisting of:
| 10-01-2009 |
| 20100105733 | Treatment of vasomotor symptoms with selective estrogen receptor modulators - The present invention is directed toward methods for treating vasomotor symptoms, (e.g., hot flashes and night sweats) in a patient in need thereof comprising administering a SERM as described herein. | 04-29-2010 |
| 20130090357 | DEUTERIUM-ENRICHED DONEPEZIL - The present application describes deuterium-enriched donepezil, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 04-11-2013 |
| 20130059888 | MEDICAMENT FOR PROPHYLACTIC AND/OR THERAPEUTIC TREATMENT OF ALZHEIMER-TYPE DEMENTIA - A medicament for prophylactic and/or therapeutic treatment of Alzheimer-type dementia, which comprises donepezil hydrochloride and valproic acid or a salt thereof in combination. | 03-07-2013 |
| 20110136868 | AGENTS FOR INHIBITING OSTEOCLASTOGENESIS AND/OR OSTEOCLAST ACTIVATION - Agents, which are both ceramide glucosyltransferase inhibitors and glucosidase inhibitors, may inhibit osteoclastogenesis and/or reduce osteoclast activation and, therefore, may be useful for osteolytic activity and bone loss in subjects with conditions, such as multiple myeloma. | 06-09-2011 |
| 20110281912 | ORAL DISPERSIBLE TABLET - The present invention relates to an oral dispersible tablet comprising at least one filler selected from sugars and sugar alcohols, and microcrystalline cellulose. | 11-17-2011 |
| 20080200507 | Crystalline Non-Solvated Methanesulfonic Acid Salt of 1-(4-(2-Piperidinylethoxy)Phenoxy)-2-(3-Hydroxyphenyl)-6-Hydroxynaphthalene - The present invention relates to the mesylate salt of 1-(4-(2-piperidinylethoxy)phenoxy)-2-(3-hydroxyphenyl)-6-hydroxynaphthalene. | 08-21-2008 |
| 20090298879 | Impurities of Donepezil - The present invention relates to impurities of donepezil, or a pharmaceutically acceptable salt thereof, which may be produced during synthesis and storage of donepezil, or a pharmaceutically-acceptable salt thereof, and to methods of identifying such impurities. The invention also relates to the use of these impurities in analytical techniques and to product that contain certain low levels of these impurities in particular the following impurities are disclosed: formula (I) and formula (II). | 12-03-2009 |
| 20090023778 | Composition Containing Anti-Dementia Drug - An object of the present invention is to provide, for the case of implementing a therapeutic method in which at least two kinds of anti-dementia drugs are used together, a composition that has a good therapeutic effect on dementia, and also gives excellent compliance. Another object of the present invention is to provide a composition containing at least two kinds of anti-dementia drugs, in which release of the anti-dementia drugs from the composition is controlled, whereby a combined effect of the anti-dementia drugs can be achieved well. Still another object of the present invention is to provide a composition for which the frequency of administration and the amount taken are reduced and hence compliance can be improved, and a method of manufacturing such a composition. According to the present invention, there is provided a composition containing at least two kinds of anti-dementia drugs; such a composition containing at least one sustained-release portion containing an anti-dementia drug; and such a composition containing at least one cholinesterase inhibitor, and at least one N-methyl-D-aspartate receptor antagonist. | 01-22-2009 |
| 20110301197 | Bis(difluoromethyl)pyrazoles as Fungicides - Bis(difluoromethyl)pyrazole derivatives of the formula (I) | 12-08-2011 |
| 20090203738 | Pharmaceutical Composition for Treating Bulimia and Depression Arising from Bulimia - Provided is a pharmaceutical composition for the treatment of bulimia in which a cholinesterase inhibitor is combined with at least one member selected from the group consisting of sibutramine, a pharmacologically acceptable salt thereof, an active metabolite thereof, a prodrug thereof and a solvate thereof. The pharmaceutical composition is useful in treating bulimia and depression arising from bulimia. | 08-13-2009 |
| 20090042940 | METHODS AND COMPOSITIONS USING CHOLINESTERASE INHIBITORS - The invention provides methods for treating and/or preventing Alzheimer's disease, psychiatric illnesses, encephalitis, meningitis, fetal alcohol syndrome, Karsakoff's syndrome, anoxic brain injury, cardiopulmonary resuscitation injuries, diabetes, Sjogren's syndrome, mental retardation, developmental delay, menopause, strokes, macular degeneration, neuronal loss associated with macular degeneration, sleep disorders, severe Alzheimer's disease, jet lag, post-traumatic stress disorder, anxiety disorders, panic attacks, obsessive-compulsive disorder, amnesia, and other disorders by administering to a patient in need thereof at least one cholinesterase inhibitor. The invention also provides novel pharmaceutical compositions that can be administered to the eyes or to the nose of patients. In one embodiment, the cholinesterase inhibitor is donepezil, a stereoisomer thereof and/or a pharmaceutically acceptable salt thereof. In other embodiments, the cholinesterase inhibitor can be one or more of phenserine, tolserine, phenethylnorcymserine, ganstigmine, epastigmine, tacrine, physostigmine, pyridostigmine, neostigmine, rivastigmine, galantamine, citicoline, velnacrine, huperzine, metrifonate, heptastigmine, edrophonium, TAK-147, T-82, and upreazine. | 02-12-2009 |
| 20080227814 | Selective Estrogen Receptor Modulators - The present invention relates to a selective estrogen receptor modulator selected from the group consisting of: (I) or a pharmaceutical salt thereof; useful, e.g., for treating endometriosis and uterine leiomyoma. | 09-18-2008 |
| 20090264467 | Agents and crystals for improving excretory potency of urinary bladder - Agents for improving potency of the urinary bladder which comprise an amine compound of non-carbamate-type having an acetylcholinesterase-inhibiting action. Particularly, crystals of a tricyclic, condensed, heterocyclic derivative are provided, which possess an excellent action to inhibit acetylcholinesterase and an action to improve the excretory potency of the urinary bladder. As an example, crystals of 8-[3-[1-[(3-fluorophenyl)-methyl]-4-piperidinyl]-1-oxopropyl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one or a salt thereof and pharmaceutical compositions containing them are disclosed. | 10-22-2009 |
| 20090137628 | Formulations of Indanylamines and the Use Thereof as Local Anesthetics and as Medication for Chronic Pain - Dermal and mucosal formulations of 2-[2-(N-phenyl-N-2-indanyl)aminoethyl]piperidine, characterized by rapid dermal and mucosal absorption and long duration of therapeutic activity are provided. Also provided are solutions of 2-[2-(N-phenyl-N-2-indanyl)aminoethyl]piperidine for injection, characterized by short onset time and long duration of activity. Formulations containing both 2-[2-(N-phenyl-N-2-indanyl)aminoethyl]piperidine and capsaicin are also provided. | 05-28-2009 |
| 20090137629 | Sigma receptor binding agent containing indanone derivative - A method for treatment of a mental disorder containing the step of administering a therapeutically effective amount of a sigma receptor binding agent containing an indanone compound represented by the following formula (I), a pharmacologically acceptable salt thereof or a hydrate of them. | 05-28-2009 |
| 20090253746 | Synthesis and Preparations of Intermediates and New Polymorphs Thereof Useful For The Preparation Of Donepezil Hydrochlcoride - The invention relates to an improved process for preparing 2-(1-benzylpiperidin-4-ylmethyliden)-5,6-dimethoxyin-dan- | 10-08-2009 |
| 20110060008 | PHARMACEUTICAL COMPOSITION CONTAINING ACETYLCHOLINE ESTERASE INHIBITOR AND METHOD FOR THE PREPARATION THEREOF - A pharmaceutical composition for oral administration comprising donepezil or pharmaceutically acceptable salt thereof, and an effective amount of pH dependent excipient as a taste masking agent, to suppress the release of donepezil in the pH environment of the oral cavity and increase the release of donepezil in acidic environment. | 03-10-2011 |
| 20090069378 | DEUTERIUM-ENRICHED DONEPEZIL - The present application describes deuterium-enriched donepezil, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 03-12-2009 |
| 20100317694 | Solid pharmaceutical composition comprising donepezil hydrochloride - The invention relates to a solid pharmaceutical composition comprising donepezil hydrochloride hydrate and a process for its preparation. In particular it relates to a composition and a process wherein the donepezil hydrochloride retains its polymorphic form and is therefore highly stable against conversion into other polymorphic forms. | 12-16-2010 |
| 20090143431 | PESTICIDE NAPHTHYLOXY SUBSTITUTED PHENYLAMIDINE DERIVATIVES - The present invention relates to 2,5-di-substituted-4-naphthyloxy-substituted-phenyl-amidine derivatives of formula (I) wherein the substituents are as in the description, their process of preparation, their use as fungicide or insecticide active agents, particularly in the form of fungicide or insecticide compositions, and methods for the control of phytopathogenic fungi or damaging insects, notably of plants, using these compounds or compositions. | 06-04-2009 |
| 20110251239 | COMBINATION THERAPY FOR THE TREATMENT OF DEMENTIA - Provided herein is a combination therapy useful for the treatment of Alzheimer's disease and Alzheimer's disease related dementia. The combination comprises memantine in an immediate or sustained release form and donepezil in a sustained release form. | 10-13-2011 |
| 20110053981 | Methods and Compositions Using Cholinesterase Inhibitors - The invention provides methods for treating and/or preventing Alzheimer's disease, psychiatric illnesses, encephalitis, meningitis, fetal alcohol syndrome, Karsakoff's syndrome, anoxic brain injury, cardiopulmonary resuscitation injuries, diabetes, Sjogren's syndrome, mental retardation, developmental delay, menopause, strokes, macular degeneration, neuronal loss associated with macular degeneration, sleep disorders, severe Alzheimer's disease, jet lag, post-traumatic stress disorder, anxiety disorders, panic attacks, obsessive-compulsive disorder, amnesia, and other disorders by administering to a patient in need thereof at least one cholinesterase inhibitor. The invention also provides novel pharmaceutical compositions that can be administered to the eyes or to the nose of patients. In one embodiment, the cholinesterase inhibitor is donepezil, a stereoisomer thereof and/or a pharmaceutically acceptable salt thereof. In other embodiments, the cholinesterase inhibitor can be one or more of phenserine, tolserine, phenethylnorcymserine, ganstigmine, epastigmine, tacrine, physostigmine, pyridostigmine, neostigmine, rivastigmine, galantamine, citicoline, velnacrine, huperzine, metrifonate, heptastigmine, edrophonium, TAK-147, T-82, and upreazine. | 03-03-2011 |
| 20080214612 | SELECTIVE ESTROGEN RECEPTOR MODULATORS CONTAINING A PHENYLSULFONYL GROUP - The present invention relates to a selective estrogen receptor modulator of formula I or a pharmaceutical acid addition salt thereof; useful, e.g., for treating endometriosis and/or uterine leiomyoma/leiomyomata. | 09-04-2008 |
| 20120302603 | AMYLOID BINDING AGENTS - There are provided compounds and methods for the detection and treatment of amyloid deposits and diseases and disorders characterized by amyloid deposits including Alzheimer's disease and related amyloid-based neurodegenerative disorders. | 11-29-2012 |
| 20110009449 | N-ARYL-N-PIPERIDIN-4-YL-PROPIONAMIDE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS - This invention relates to N-aryl-N-piperidin-4-yl-propionamide derivatives for use as monoamine neurotransmitter re-uptake inhibitors. | 01-13-2011 |
| 20110136867 | Treatment of Synucleinopathies - Methods and compositions useful in the treatment or prevention of synucleinopathies, such as Parkinson's Disease, Diffuse Lewy Body Disease, and Multiple System Atrophy, or other neurodegenerative diseases are provided. The treatment including administering to a subject a farnesyl transferase inhibitor compound. | 06-09-2011 |
| 20110218218 | Formulations Of Indanylamines And The Use Thereof As Local Anesthetics And As Medication For Chronic Pain - Internal-dermal formulations of RS—, S—, or R-2-[2-(N-phenyl-N-2-indanyl)aminoethyl]piperidine causing intradermal accumulation of said piperidine and intended for the treatment of neuropathic pain are provided, as well as a method of inducing the relief of pain using the compounds. | 09-08-2011 |
| 20110218217 | PIPERIDYLPROPIONAMIDE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS INCLUDING DEPRESSION AND PANIC DISORDER - This invention relates to novel piperidine-4-propionamide derivatives useful as monoamine neurotransmitter re-uptake inhibitors. In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention. | 09-08-2011 |
| 20110218216 | EXTENDED RELEASE PHARMACEUTICAL COMPOSITION OF DONEPEZIL - The present invention relates to an extended release pharmaceutical composition for oral administration comprising donepezil or pharmaceutically acceptable salt thereof and a release-controlling agent. Further, it relates to process for preparation of said compositions. | 09-08-2011 |
| 20090156639 | COMPOSITIONS AND METHODS OF TREATMENT USING L-TYPE CALCIUM CHANNEL BLOCKERS AND CHOLINESTERASE INHIBITORS - The present invention relates to composition comprising at least one L-type calcium channel blocker, particularly the compound (+)-isopropyl 2-methoxyethyl 4-(2-chloro-3-cyano-phenyl)-1,4-dihydro-2,6-dimethyl-pyridine-3,5-dicarboxylate, in combination with at least one cholinesterase inhibitor, particularly donepezil, and uses thereof in methods of treatment. | 06-18-2009 |
| 20110086880 | NOVEL ALKYL SUBSTITUTED PIPERIDINE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS - This invention relates to novel alkyl substituted piperidine derivatives useful as monoamine neurotransmitter re-uptake inhibitors. In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention. | 04-14-2011 |
| 20090036487 | Combinations - The instant invention relates to a combination of an alpha-2-delta ligand and an AChE inhibitor for use in therapy, particularly in the treatment of pain, particularly neuropathic pain. Particularly preferred alpha-2-delta ligands are gabapentin and pregabalin. Particularly preferred AChE inhibitors are donepezil (Aricept®), tacrine (Cognex®), rivastigmine (Exelon®), physostgmine (Synapton®), galantamine (Reminyl), metrifonate (Promem), neostigmine (Prostigmin) and icopezil. | 02-05-2009 |
| 20110053980 | INDANE-AMINE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS - The present invention relates to indane-amine compounds of general formula (I) and compositions thereof, methods for their preparation, and the use of said compounds for the preparation of a medicament for the treatment of humans or animals. | 03-03-2011 |
| 20120010243 | METHODS FOR TREATING DISORDERS OR DISEASES ASSOCIATED WITH HYPERLIPIDEMIA AND HYPERCHOLESTEROLEMIA WHILE MINIMIZING SIDE EFFECTS - The present invention provides methods and compositions for treating hyperlipidemia and/or hypercholesterolemia comprising administering to the subject an effective amount of an MTP inhibitor to inhibit hyperlipidemia and/or hypercholesterolemia in said subject, wherein said administration comprises an escalating series of doses of the MTP inhibitor. In some embodiments the method comprises administering at least three step-wise, increasing dosages of the MTP inhibitor to the subject. In some embodiments, the method further comprises the administration of one or more other lipid modifying compounds. | 01-12-2012 |
| 20100048628 | METHOD FOR SUPPRESSING DISCOLORATION OVER TIME OF ADHESIVE PREPARATION CONTAINING DONEPEZIL - [Object] Discoloration, over time, of a donepezil-containing adhesive preparation is suppressed. | 02-25-2010 |
| 20120029017 | PECTIN-CONTAINING JELLY FORMULATION - There is disclosed a technique for making a jelly formulation comprising pectin slide out of a container easily (improving the slidability of the jelly formulation) when taking the formulation out of the container to prevent the formulation from remaining in the container. The jelly formulation of the present invention comprises a drug, pectin, divalent metal ions, and polyoxyethylene polyoxypropylene glycol. | 02-02-2012 |
| 20110077271 | Process for the Preparation of Donepezil Hydrochloride - The present invention provides a process for preparing donepezil or a salt thereof, the process comprising reducing a 1-benzyl-4-[(5,6-dimethoxy-1-indanon-2-yl)methylene]pyridonium halide of formula II, wherein X is bromide or chloride, in the presence of an ionic compound, a solvent, a catalyst and a source of hydrogen, to form donepezil and optionally converting the donepezil to the salt thereof. | 03-31-2011 |
| 20110046179 | NOVEL PIPERIDINE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS - This invention relates to novel piperidine derivatives useful as monoamine neurotransmitter re-uptake inhibitors. | 02-24-2011 |
| 20100016362 | STABILIZED PHARMACEUTICAL COMPOSITION CONTAINING DONEPEZIL, PROCESS OF PRODUCING SAME AND METHOD FOR STABILIZATION - An object of the present invention is to provide a novel pharmaceutical composition containing donepezil, which is already used as a remedy for the treatment of dementia (cognitive impairment), in order to increase options for administration methods and improve patient compliance. The present invention provides a pharmaceutical composition containing donepezil or a pharmaceutically acceptable salt thereof and a naturally-occurring polymer, the pharmaceutical composition further containing at least one of edetate, sulfite, dibutylhydroxytoluene and butylhydroxyanisole. | 01-21-2010 |
| 20110065749 | METHOD AND PHARMACEUTICAL COMPOSITION FOR TREATMENT OF MENTAL DISORDERS - A method of treating a mental disorder including administering to a patient in need thereof, an effective amount of a pharmaceutical composition including 1,1-diphenyl-4-piperidine-1-ylbuthan-1-ol or a pharmaceutically acceptable salt thereof. The mental disorder is depression, bipolar disorder, anxiety disorder, impulsive disorder, bulimia, panic disorder, social anxiety disorder, insomnia, attention deficit hyperactivity disorder (ADHD), schizophrenia, dementia, personality disorder, alcoholism, dissociative disorder, sleep apnea syndrome, or fibromyalgia. In a preferred embodiment, the mental disorder as a therapeutic target is fibromyalgia, chronic fatigue syndrome (CFS), or depression with pain, and the administration of the pharmaceutical composition is capable of reducing the pain caused by these diseases. | 03-17-2011 |
| 20120252842 | COMPOSITIONS, SYNTHESIS, AND METHODS OF USING INDANONE BASED CHOLINESTERASE INHIBITORS - The present invention provides novel indanone derivatives which can be advantageously used for treating and/or preventing of a medical condition for which inhibition of a cholinesterase is desired. | 10-04-2012 |
| 20120129888 | LIBRARIES OF N-(2-OXO-1-PHENYLPIPERIDIN-3-YL)SULFONAMIDES FOR DRUG DISCOVERY - Novel compounds are continually sought after to treat and prevent disorders. The invention relates to N-(2-oxo-1-phenylpiperidin-3-yl)sulfonamides useful for contributing to the search and identification of new lead compounds which can modulate the functional activity of a biological target. | 05-24-2012 |
| 20100173940 | NON-MUCOADHESIVE FILM DOSAGE FORMS - Orally disintegrating film dosage forms for delivering active pharmaceutical agents, methods of formulating the dosage forms to retard absorption through the oral mucosa, and methods of using the dosage forms for the treatment of various medical conditions are provided. | 07-08-2010 |
| 20100010043 | PERCUTANEOUSLY ABSORBABLE PREPARATION - The present invention provides a percutaneously absorbable preparation comprising 2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxyindan-1-one and/or a hydrochloride thereof wherein the percuneously absorbable preoaration is able to administer to a patient such that Cmax per unit surface area of the percutaneously absorbable preparation is 0.025 to 0.5 ng/ml·cm | 01-14-2010 |
| 20120220629 | ASYMMETRIC UREAS AND MEDICAL USES THEREOF - Disclosed are compounds, compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the ghrelin receptor. The compounds have the general formula (I): | 08-30-2012 |
| 20120220628 | TABLETS COMPRISING A TASTE MASKING AGENT - The present invention is directed to a tablet comprising at least one bitter tasting and/or mucosa numbness causing pharmaceutically active compound; and at least one zinc salt. In addition, the present invention relates to the use of a zinc salt to reduce or mask the bitter taste of or the numbness of the mucosa caused by pharmaceutically active compounds. | 08-30-2012 |
| 20120190710 | BICYCLO-HEPTAN-2-AMINES - The present invention provides bicyclo-heptan-2-amines that selectively bind to the sigma-2 receptor and are useful in the treatment of diseases related to the sigma-2 receptor, for example, cancer and neurological disorders. | 07-26-2012 |
| 20120264782 | COMPOSITIONS FOR THE TREATMENT OF CNS-RELATED CONDITIONS - The invention provides compositions comprising extended release memantine in combination with immediate release donepezil to a subject. Memantine in an extended release form containing 22.5 to 30 mg memantine or a pharmaceutically acceptable salt thereof in combination with donepezil achieves particular pharmacokinetic criteria such as change in plasma concentration of memantine over time and ratio of maximum memantine plasma concentration to mean memantine plasma concentration. | 10-18-2012 |
| 20120264783 | METHODS FOR THE TREATMENT OF CNS-RELATED CONDITIONS - The invention provides methods for administering extended release memantine in combination with immediate release donepezil to a subject. Memantine in an extended release form containing 22.5 to 30 mg memantine or a pharmaceutically acceptable salt thereof in combination with donepezil is administered to a patient suffering from a neurological condition, such as Alzheimer's disease, Parkinson's disease or dementia. The extended release form of memantine achieves particular pharmacokinetic criteria such as change in plasma concentration of memantine over time and ratio of maximum memantine plasma concentration to mean memantine plasma concentration. | 10-18-2012 |
| 20080300274 | Novel Pyrrolidino-1,4-Naphthoquinone Deriviatives and their Use for Treating Malignancies and Cardiovascular Diseases - The invention provides pyrrolidino-substituted 1,4-naphthoquinone derivatives that modulate the activity of protein kinases, and it relates to the use of the derivatives in pharmaceutical compositions for treating cardiovascular disorders and malignancies. The invention particularly provides medicaments for treating disorders associated with MAPKs signaling, ERKs signaling, p38 signaling, and JNKs signaling. | 12-04-2008 |
| 20120270901 | INDENE DERIVATIVES AS PHARMACEUTICAL AGENTS - Compounds of formula (Ia): | 10-25-2012 |
| 20090042939 | Methods and Compositions Using Cholinesterase Inhibitors - The invention provides methods for treating and/or preventing Alzheimer's disease, psychiatric illnesses, encephalitis, meningitis, fetal alcohol syndrome, Karsakoff's syndrome, anoxic brain injury, cardiopulmonary resuscitation injuries, diabetes, Sjogren's syndrome, mental retardation, developmental delay, menopause, strokes, macular degeneration, neuronal loss associated with macular degeneration, sleep disorders, severe Alzheimer's disease, jet lag, post-traumatic stress disorder, anxiety disorders, panic attacks, obsessive-compulsive disorder, amnesia, and other disorders by administering to a patient in need thereof at least one cholinesterase inhibitor. The invention also provides novel pharmaceutical compositions that can be administered to the eyes or to the nose of patients. In one embodiment, the cholinesterase inhibitor is donepezil, a stereoisomer thereof and/or a pharmaceutically acceptable salt thereof. In other embodiments, the cholinesterase inhibitor can be one or more of phenserine, tolserine, phenethylnorcymserine, ganstigmine, epastigmine, tacrine, physostigmine, pyridostigmine, neostigmine, rivastigmine, galantamine, citicoline, velnacrine, huperzine, metrifonate, heptastigmine, edrophonium, TAK-147, T-82, and upreazine. | 02-12-2009 |
| 20110237623 | SUSTAINED-RELEASE DONEPEZIL FORMULATION - A sustained-release formulation for an acetylcholinesterase inhibitor, comprising an acetylcholinesterase inhibitor and at least two gel-forming polymers, and methods of manufacture thereof. The acetylcholinesterase inhibitor preferably comprises donepezil. | 09-29-2011 |
| 20120088794 | AMINOTETRALIN COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS - The invention provides aminotetralin compounds of formula (I): | 04-12-2012 |
| 20110275670 | New Compounds VII - The present invention relates to new compounds of formula (I), to pharmaceutical compositions comprising these compounds and to the use of these compounds as leptin receptor modulator mimetics in the preparation of medicaments against conditions associated with weight gain, type 2 diabetes and dyslipidemias. | 11-10-2011 |
| 20120329831 | PHARMACEUTICAL COMPOSITION OF DONEPEZIL - The present invention relates to a pharmaceutical composition of donepezil or pharmaceutically acceptable salts thereof comprising ethyl cellulose and methacrylic acid copolymer in a ratio of more than 1.3. Further, it relates to process for preparation of said composition. | 12-27-2012 |
| 20120283291 | SOLID PHARMACEUTICAL COMPOSITION COMPRISING DONEPEZIL HYDROCHLORIDE - The invention relates to a solid pharmaceutical composition comprising donepezil hydrochloride hydrate and a process for its preparation. In particular it relates to a composition and a process wherein the donepezil hydrochloride retains its polymorphic form and is therefore highly stable against conversion into other polymorphic forms. | 11-08-2012 |
| 20110160246 | Neurodegenerative Protein Aggregation Inhibition Methods and Compounds - Methods and compositions are provided for reducing aggregation of neurodegenerative proteins associated with neurotoxicity or other proteins. The compounds comprise a first domain or targeting element for binding to the target proteins linked to a second domain or recruiting element that binds to an aggregation inhibiting protein, e.g. a prolyl isomerase. By associating the aggregating forming proteins or neuronal cells under conditions where aggregating proteins are produced with the compound and the aggregation inhibiting protein, aggregation is reduced. The subject agents can be used in assays, investigating the etiology of the neuronal diseases and for prophylaxis and therapy. | 06-30-2011 |
